![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
DRUG INTERACTION PROFILE OF TELAPREVIR
|
|
|
Reported by Jules Levin
22nd Conference of the Asian Pacific Association for the Study of the Liver (APASL), Taipei, Taiwan, February 16-19, 2012
Varun Garg*1, Robert S Kauffman1, Maria Beumont2, Rolf van Heeswijk2
1Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA; 2Janssen Infectious Diseases BVBA, Beerse, Belgium
![APSL1.gif](../images/022212/022212-6/APSL1.gif)
![APSL2.gif](../images/022212/022212-6/APSL2.gif)
![APSL3.gif](../images/022212/022212-6/APSL3.gif)
![APSL4.gif](../images/022212/022212-6/APSL4.gif)
![APSL5.gif](../images/022212/022212-6/APSL5.gif)
![APSL6.gif](../images/022212/022212-6/APSL6.gif)
![APSL7.gif](../images/022212/022212-6/APSL7.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|